Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cancer Research|May 6, 2004
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivoYoung Trieu, Xiao-Yan Wen, Brian F Skinnider, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 18, 2010
Synergistic interaction between oncolytic viruses augments tumor killingFabrice Le Boeuf, Jean-Simon Diallo, J Andrea McCart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flowCaroline J Breitbach, Jennifer M Paterson, Chantal G Lemay, et al.
Biomedicines|May 25, 2017
Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus MacaquesBryan C Au, Chyan-Jang Lee, Orlay Lopez-Perez, et al.
Plos One|February 2, 2011
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitorsHeather MacTavish, Jean-Simon Diallo, Baocheng Huang, et al.
Cancer Research|February 9, 2013
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humansCaroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, et al.
Molecular Therapy Oncolytics|December 3, 2016
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodiesLaura Evgin, Carolina S Ilkow, Marie-Claude Bourgeois-Daigneault, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLaura Evgin, Sergio A Acuna, Christiano Tanese de Souza, et al.
Oncoimmunology|December 15, 2018
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trialsJonathan G Pol, Sergio A Acuna, Beta Yadollahi, et al.
Pageof 5